Three med tech companies recently have disclosed their intentions to go public. These include breast implant maker Sientra, noninvasive neurostimulation player Nexstim and rheumatology diagnostics company Exagen.
In one of the largest medical device venture rounds this year, eye care company Ivantis today announced that it has raised an additional $25 million in its Series B financing, taking the total to $71 million for the developer of a tiny intracanalicular scaffold for glaucoma patients.
The bloodletting in Big Pharma continues with news today that Boehringer Ingelheim is planning between 500 and 600 job cuts in its home country of Germany. The cuts come just a few weeks after the company announced its sales had dropped 3% in the first 6 months of the year and full-year results would likely be down slightly from last year.
Treasury Secretary Jacob Lew yesterday unveiled a plethora reforms to make tax inversion more difficult and less attractive, potentially killing a plethora of pending mergers with foreign companies, including Medtronic's $43 billion tie-up with Ireland's Covidien.
On the heels of a $42 million Series F closed last fall, CVRx is picking up an additional $15 million in a debt facility from Silicon Valley Bank. But that's chump change in the long run for this startup, which has raised about $265 million since its 2001 inception.
iHealth is not new to the mobile health device game. Launched in 2010, as a subsidiary of medical device manufacturer Andon Health--it markets several mobile-compatible devices including blood pressure and blood glucose monitors. In fact, iHealth had the first health device carried in Apple retail stores.
Phibro Animal Health reported a 12% increase in fiscal fourth-quarter sales, spurred by gains in its animal growth and mineral nutrition divisions.
The Association of Clinical Research Organizations, which represents the world's largest CROs, polled its membership and found that the industry's biggest players have seen their revenues and payrolls skyrocket over the past decade, claiming an increasingly large share of global R&D spends.
SiSaf, a Northern Ireland-based drug delivery company, has announced it plans to enter into the veterinary and animal health sector.
Who's afraid of a tax-inversion crackdown? Not Illinois-based Horizon Pharma, which plans to move its corporate address to Ireland today.